SCHEMBL7262198

SCHEMBL7262198

Cc1ccc([O])c(C=Cc2ccccc2Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 1/20 0.44
FGFR3 P22607 1/20 0.44
RAB9A P51151 6/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
CYP1A2 P05177 2/20 0.43
CYP1A1 P04798 1/20 0.43
CYP1B1 Q16678 1/20 0.43
NPC1 O15118 5/20 0.41
MAPT P10636 4/20 0.41
KMT2A Q03164 4/20 0.41
MEN1 O00255 3/20 0.41
CHAT P28329 1/20 0.41
POLB P06746 3/20 0.40
CASP3 P42574 1/20 0.40
SENP7 Q9BQF6 1/20 0.40
SENP6 Q9GZR1 1/20 0.40
NFE2L2 Q16236 2/20 0.40
RELA Q04206 1/20 0.40
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4714522 0.81 MEN1 (0.47) FGFR1FGFR3RAB9ASMN1; SMN2CYP1A2
SCHEMBL4714523 0.81 MEN1 (0.47) FGFR1FGFR3RAB9ASMN1; SMN2CYP1A2
SCHEMBL7262186 0.81 CYP1A2 (0.43) FGFR1FGFR3RAB9ASMN1; SMN2CYP1A2
SCHEMBL4713060 0.80 RAB9A (0.46) FGFR1FGFR3RAB9ASMN1; SMN2CYP1A2
SCHEMBL4713064 0.80 RAB9A (0.46) FGFR1FGFR3RAB9ASMN1; SMN2CYP1A2
SCHEMBL4711231 0.78 FGFR1 (0.41) FGFR1FGFR3RAB9ASMN1; SMN2CYP1A2
SCHEMBL4711228 0.78 FGFR1 (0.41) FGFR1FGFR3RAB9ASMN1; SMN2CYP1A2
SCHEMBL4710055 0.76 KMT2A (0.44) FGFR1FGFR3RAB9ASMN1; SMN2NPC1
SCHEMBL7267902 0.76 FGFR1 (0.44) FGFR1FGFR3RAB9ASMN1; SMN2NPC1
SCHEMBL4710053 0.76 KMT2A (0.44) FGFR1FGFR3RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1203060-C Pyridine derivatives, compositions and uses thereof NOVARTIS AG (CH) 2005-05-25 CN disclosed
US-6656957-B1 Marked and selective modulating, especially antagonistic, action at human metabotropic glutamate receptors (mGluRs); treatment of disorders such as epilepsy, cerebral ischemias, especially acute ischemias, spasticity etc. NOVARTIS AG (CH) 2003-12-02 US disclosed
CN-1262676-A Pyridine derivatives NOVARTIS AG (CH) 2000-08-09 CN disclosed